KRAS and non-small cell lung carcinoma: For example, as shown in a study performed in non–small cell lung cancer (NSCLC) cell lines, not all activating KRAS mutations are clinically equivalent because various forms of Ras oncoproteins exhibit different types of biological behavior, have different effects on downstream signaling pathways and thus may also have different effects on patient prognosis [19].